Roche Acquires Novel TMEM16A Potentiator Portfolio from Enterprise Therapeutics

October 7, 2020

Enterprise Therapeutics has announced that its novel TMEM16A potentiator portfolio has been fully acquired by Roche

Enterprise Therapeutics has announced, in an Oct. 7, 2020 press release, that its novel TMEM16A potentiator portfolio has been fully acquired by Roche. Development of the portfolio, which includes ETD002—a compound currently in Phase I trials—will be performed by Genentech.

The TMEM16A portfolio is aimed at the treatment of all people with cystic fibrosis and has the potential to benefit others with severe respiratory diseases that are characterized by excessive mucus congestion. ETD002 has been demonstrated to enhance the activity of TMEM16A, an alternative anion channel present in airway epithelial cells, in pre-clinical models by Enterprise.

“Roche and Genentech have a proven track record of bringing new medicines to people with respiratory diseases, and have recognized the opportunity that our TMEM16A potentiator portfolio presents,” said Dr. John Ford, CEO, Enterprise Therapeutics, in the press release. “I am very proud of the team at Enterprise for identifying and developing this innovative approach to treat patients, with ETD002 the first of our compounds to reach clinical stage. TMEM16A potentiation has the potential to significantly increase the quality of life for people living with cystic fibrosis, for many of whom existing therapies are not effective.”

Dr. James Sabry, global head of Pharma Partnering, Roche, added, in the press release, “We are excited to add Enterprise’s TMEM16A potentiator program to our existing respiratory portfolio. We have deep capabilities in this area and look forward to a robust program focused on helping cystic fibrosis patients and patients suffering from other muco-obstructive disorders as quickly as possible.”

Shareholders of Enterprise Therapeutics have received an upfront payment of £75 million (US $97 million) and are eligible to receive additional contingent payments should specific predetermined milestones be met.

Source: Enterprise Therapeutics